FSHD
Sponsor study identifier
interventional
10
1 country
2
Study Start
January 19, 2025
Actual (reported)Primary Completion
April 26, 2026
Actual (reported)Study Completion
April 26, 2026
Actual (reported)Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common types of muscular dystrophy, affecting about 4 out of 100,000 individuals. The disease is characterized by progressive muscle loss (i.e., muscle atrophy) commonly affecting the face, shoulders, and upper arm muscles. The muscle loss ultimately results in reduced strength and impaired physical performance. At present there is no cure for FSHD, therefore, physicians have focused on therapeutic interventions to help alleviate these symptoms. Daily consumption of adequate amounts of dietary protein is essential to support muscle mass maintenance and overall health and function across the lifespan. However, previous research has reported inadequate protein intake in individuals with FSHD. The characteristic of progressive muscle loss in individuals with FSHD and other muscular dystrophies is ultimately due to an imbalance in the rate of muscle building (i.e., muscle protein synthesis) and muscle breakdown (i.e., muscle protein breakdown), where individuals with FSHD have been shown to have reduced rates of muscle building. As inadequate protein intake is known to result in a loss of muscle mass, strength and function, this loss may be amplified in individuals with FSHD. Dietary recommendations traditionally have been determined through nitrogen balance techniques, where the current recommended dietary allowance (RDA) for daily protein intake for adults is 0.8 g/kg/d. However, recent research indicates how the nitrogen balance technique potentially underestimates protein requirements. Therefore, there is a need to reassess current dietary recommendations in adults with FSHD in order to help support the maintenance of muscle strength and function. Recent efforts to understand protein requirements in various populations have been completed using the indicator amino acid oxidation technique (IAAO). This non-invasive method is reported to provide a robust measure of protein requirements. Due to its non-invasive nature, the IAAO method allows researchers to use this technique in individuals with FSHD, where there is currently limited work in studying this population. The purpose of this study is to measure the protein requirements in individuals with FSHD using the non-invasive IAAO technique.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 26, 2026
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 16, 2025
Actual (reported)January 19, 2025
Actual (reported)January 21, 2025
Actual (reported)April 26, 2026
Actual (reported)April 26, 2026
Actual (reported)13CO2 Excretion
Measured by continuous-flow isotope ratio mass spectrometry
7-weeks
L-[13C]-Phenylalanine Oxidation
7-weeks
Participants are to be randomly assigned varying levels of amino acid intakes ranging between 0.2 to 2.8 g/kg/d.
Amino acid intakes will vary between 0.2 to 2.8 g/kg/d.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
McGill university
Montreal, Quebec, H2W 1S4, Canada
McGill university
Montreal, Quebec, H3A 0G4, Canada
10 participants (actual enrollment reported by the registry).
First Submitted
January 16, 2025
First Posted
January 21, 2025
Study Start
January 19, 2025
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
April 26, 2026
Actual (reported)Study Completion
April 26, 2026
Actual (reported)Last Updated
July 9, 2026
Record last verified: 2026-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: